Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Alzheimer’s & dementia stories

Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Oct 29, 2026

Older adults' brains adapt better to sleep deprivation, Simon Fraser University study finds

Research from Simon Fraser University reveals that older adults' brains cope more effectively with lack of sleep compared to younger individuals, according to findings published in Imaging Neuroscience using functional connectivity analysis.

Oct 29, 2026·1 source
00

Sutter Health review board improves access to anti-amyloid Alzheimer's therapies

Sutter Health has implemented a review board system to more efficiently process referrals for anti-amyloid therapies that slow Alzheimer's disease progression, as demand for these treatments increases. The approach aims to streamline access to these disease-modifying treatments for eligible patients.

Oct 29, 2026·2 sources
00

International study identifies 127 genetic risk regions for Alzheimer's disease

A large-scale multi-ancestry genetic study led by Ole Andreassen at University of Oslo has identified new DNA risk factors for Alzheimer's disease, implicating microglial and neuronal dysregulation. The research reveals a larger common-variant contribution to the disease than previously estimated and identifies potential new drug targets.

Oct 29, 2026·3 sources
00
Oct 19, 2026

Carotid artery stenting fails to improve cognition in CREST-H clinical trial

A Columbia-led clinical trial published in JAMA found that opening blockages in the brain's main blood vessels through stenting or surgery does not improve cognitive function, despite hopes that improved blood flow would enhance cognition in patients with clogged carotid arteries.

Oct 19, 2026·1 source
00

Gut microbiome study identifies potential early markers for dementia risk

Researchers from Cardiff University and Imperial College London conducted the first study examining both gut bacteria and chemicals to identify people at risk of dementia. The findings could support earlier diagnosis and help identify individuals at risk of faster cognitive decline.

Oct 19, 2026·2 sources
00

Walking 3,000 steps daily may slow Alzheimer's tau protein buildup, study finds

New research tracking nearly 300 older adults with early Alzheimer's signs for 9-11 years found that walking just 3,000 steps daily was linked to reduced tau protein buildup and nearly half the cognitive decline, though it didn't affect amyloid levels. The findings suggest even low levels of physical activity could protect the brain from Alzheimer's progression.

Oct 19, 2026·1 source
00
Oct 14, 2026

Arrowhead Pharmaceuticals' ARO-MAPT shows first evidence of tau protein reduction in Alzheimer's trial

Arrowhead Pharmaceuticals reported interim Phase 1/2a results showing its experimental RNA interference drug ARO-MAPT successfully crossed the blood-brain barrier and reduced levels of tau protein, a key marker implicated in Alzheimer's disease. The subcutaneously administered treatment represents the first RNAi medicine to achieve this effect in the brain, with analysts describing the magnitude of tau reduction as compelling and potentially superior to other blood-brain barrier platforms.

Oct 14, 2026·4 sources
00
Oct 12, 2026

Routine hemoglobin blood test may predict long-term dementia risk, study finds

A study of 316,542 Korean adults presented at the ECNP Congress in Munich found that a common blood test already used in routine health checks may contain clues about a person's long-term risk of developing dementia. The research was published in the Journal of Alzheimer's Disease.

Oct 12, 2026·2 sources
00
Sep 25, 2026

Washington University finds Alzheimer's immune cells may originate in lymph nodes outside brain

Researchers at Washington University School of Medicine discovered that immune cells contributing to Alzheimer's-related brain damage may be activated in lymph nodes outside the brain before traveling into the nervous system. Blocking this pathway in mice dramatically reduced neurodegeneration and preserved cognitive abilities.

Sep 25, 2026·3 sources
00

Glucosamine supplement linked to faster Alzheimer's progression in new study

University of Florida researchers found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify abnormal sugar-tagging processes in the Alzheimer's brain, though the observational study does not prove causation.

Sep 25, 2026·5 sources
00

Blood-based biomarkers reshape Alzheimer's disease diagnostic approach

Medical experts are sequencing plasma p-tau217 and beta-amyloid 42/40 testing alongside cognitive screening as first-line diagnostic tools for Alzheimer's disease, reserving confirmatory amyloid PET or CSF testing for inconclusive cases. Payer coverage for these biomarker tests has expanded, marking a shift in the diagnostic toolkit.

Sep 25, 2026·3 sources
00
Sep 24, 2026

Acadia's Alzheimer's psychosis drug fails mid-stage trial

Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.

Sep 24, 2026·3 sources
00
Sep 20, 2026

Clinical trials face severe patient recruitment shortage across cancer and Alzheimer's disease

Clinical trials for major diseases are experiencing a critical shortage of participants, with only 7% of adult cancer patients in the U.S. enrolling in trials and Alzheimer's treatment studies facing similar global recruitment challenges despite new drug developments.

Sep 20, 2026·2 sources
00
Sep 18, 2026

Growing evidence suggests Alzheimer's disease may be transmissible in rare medical cases

A small but growing body of research is examining whether Alzheimer's disease can be transmitted through certain medical procedures, exploring the concept of 'iatrogenic' AD. While the disease is not contagious through normal contact, scientists are investigating rare cases of potential medical transmission.

Sep 18, 2026·1 source
00
Aug 24, 2026

FDA clears Roche and Eli Lilly's blood test for Alzheimer's disease detection

The FDA has cleared a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.

Aug 24, 2026·3 sources
00
Aug 14, 2026

Brain autopsies reveal fewer Alzheimer's signs in woman who took menopause drug

Autopsy findings show reduced Alzheimer's pathology in a woman who used menopause medication, suggesting potential protective effects of hormone therapy on brain health.

Aug 14, 2026·2 sources
00

FDA approves Enigma Biomedical's TAUKLARIFY for Alzheimer's disease diagnosis

The FDA has approved TAUKLARIFY (florquinitau F 18 injection), a novel diagnostic imaging agent developed by Enigma Biomedical USA to identify tau neurofibrillary tangles in patients being evaluated for Alzheimer's disease, including tangles isolated to the medial temporal lobe.

Aug 14, 2026·1 source
00

Women taking estrogen-only hormone therapy showed fewer Alzheimer's signs in brain tissue

A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.

Aug 14, 2026·3 sources
00
Aug 7, 2026

New research reveals dual mechanisms behind Parkinson's disease: protein transport blockage and astrocyte disruption

Two recent studies illuminate different cellular mechanisms in Parkinson's disease: one showing how alpha-synuclein protein clumps block waste recycling in neurons, and another revealing that the LRRK2-G2019S mutation disrupts development of astrocytes, the brain's support cells.

Aug 7, 2026·2 sources
00
Aug 6, 2026

Study Links Three Midlife Health Factors to 13 Additional Dementia-Free Years

New research published in Neurology Open Access finds that maintaining normal blood pressure, avoiding type 2 diabetes, and not smoking between ages 45-68 is associated with nearly 13 more years of dementia-free life after age 55 compared to those with all three risk factors.

Aug 6, 2026·9 sources
00

Study Reveals Aging Human Brains Replace Resident Immune Cells with Blood-Derived Cells Starting at Age 50

Researchers have overturned longstanding scientific dogma by discovering that beginning around age 50, the brain's memory center loses its longtime resident immune cells (microglia) and replaces them with more inflammatory immune cells derived from peripheral blood stem cells. This previously unrecognized migration may help explain how normal aging sets the stage for Alzheimer's disease and dementia.

Aug 6, 2026·6 sources
00

Scientists Discover Immune Cell Migration from Blood to Brain Beginning at Age 50

Researchers have overturned long-held scientific understanding by discovering that aging human brains undergo a massive influx of peripheral blood-derived immune cells starting around age 50, replacing resident microglia with more inflammatory cells. This shift may help explain how normal aging sets the stage for Alzheimer's disease and dementia.

Aug 6, 2026·5 sources
00

Stanford and UCSF researchers discover tau protein infiltrates mitochondria, disrupting energy production in Alzheimer's disease

Scientists at Stanford University School of Medicine and University of California, San Francisco have identified a novel toxic mechanism in which hyperphosphorylated tau protein enters nerve cell mitochondria and reverses electron flow, potentially driving Alzheimer's disease and other neurodegenerative tauopathies.

Aug 6, 2026·7 sources
00
Aug 5, 2026

Study Finds Most Patients with Atypical Alzheimer's Ineligible for New Anti-Amyloid Therapies

Research published in Neurology on August 5, 2026 reveals that up to 85 percent of people with less common forms of Alzheimer's disease may not qualify for newer anti-amyloid treatments designed to slow disease progression.

Aug 5, 2026·3 sources
00
Aug 3, 2026

APOE2 gene protects brain from Alzheimer's by reducing DNA damage

Research shows the longevity-linked APOE2 gene protects brain cells by reducing DNA damage and helping neurons recover from stress, potentially opening new treatment paths for Alzheimer's disease.

Aug 3, 2026·1 source
00
Aug 1, 2026

Dementia risk factors differ widely across countries, challenging one-size-fits-all prevention

Analysis of data from more than 214,000 people found that dementia risk factors vary significantly across countries, suggesting prevention strategies need to be tailored to local populations.

Aug 1, 2026·1 source
00

New AI-powered diagnostic tools promise earlier, faster detection of Alzheimer's disease

Multiple breakthrough technologies for Alzheimer's detection are emerging, including a blood test that delivers results in 18 minutes, AI analysis of brain scans requiring minimal computing power, and machine learning that identifies dementia risk through sleep EEG patterns years before symptoms appear.

Aug 1, 2026·5 sources
00
Jul 26, 2026

Phase 2 Clinical Trial Shows THC-CBD Combination Rapidly Reduces Agitation in Advanced Dementia Patients

The LiBBY clinical trial found that a combination of CBD and THC rapidly and significantly reduced agitation in hospice-eligible dementia patients, with nearly 90% of participants showing behavioral improvement in the nationwide study.

Jul 26, 2026·3 sources
00
Jul 15, 2026

Blood Test Using P-Tau217 Biomarker Can Predict Alzheimer's Risk Years Before Symptoms Appear, Study Finds

A new study demonstrates that a blood test measuring p-tau217 levels can identify healthy older adults at high risk of developing Alzheimer's symptoms within five to 10 years, potentially enabling early intervention as prevention trials advance.

Jul 15, 2026·5 sources
00

WHO Releases Updated Guidelines Saying Up to 45% of Dementia Risk Could Be Prevented or Delayed

The World Health Organization has issued updated global guidelines on reducing cognitive decline and dementia risk, stating that up to 45% of dementia cases may be preventable or delayed by addressing modifiable risk factors throughout life.

Jul 15, 2026·5 sources
00
Jul 14, 2026

Experimental Alzheimer's drug targeting tau protein shows promise in slowing cognitive decline

An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.

Jul 14, 2026·8 sources
00
Jun 24, 2026

ALZpath Signs Global Licensing Agreement with Abbott Laboratories for Alzheimer's Blood Test Development

ALZpath announced a global licensing deal with Abbott Laboratories to advance blood-based testing for Alzheimer's disease, joining the race to develop easier-to-use diagnostic options for the neurodegenerative condition.

Jun 24, 2026·1 source
00
May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source
00
May 11, 2026

Medicare Spending on Alzheimer's Drugs Falls Far Short of Projections

Federal data shows far fewer Medicare beneficiaries than expected are taking recently approved Alzheimer's medications, with adoption remaining slow due to complex administration requirements and uncertain benefits.

May 11, 2026·3 sources
00
May 1, 2026

Axsome Wins FDA Approval for Alzheimer's Agitation Treatment

The FDA has approved Axsome's drug for treating agitation in Alzheimer's disease patients, marking a new therapeutic option for this challenging symptom.

May 1, 2026·1 source
00
Apr 23, 2026

Dopamine Loss Emerges as Key Driver of Memory Decline in Alzheimer’s

Study finds reduced dopamine signaling contributes to memory decline in Alzheimer’s, highlighting a previously underrecognized pathway and potential target for treatment.

Apr 23, 2026·3 sources
00
Apr 20, 2026

Gut Microbiome Analysis Can Predict Parkinson's Disease Risk Before Symptoms Appear

New research led by University College London shows that analysis of gut microbes can reveal elevated Parkinson's disease risk before any symptoms develop, offering potential for early intervention.

Apr 20, 2026·1 source
00

FDA Approves At-Home Starting Dose for Eisai-Biogen Alzheimer's Drug

The U.S. Food and Drug Administration approved an at-home starting dose of Eisai and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver rather than requiring initial doses in a clinical setting.

Apr 20, 2026·2 sources
00
Apr 17, 2026

Optimism Linked to 15% Lower Dementia Risk in 14-Year Study

Harvard T.H. Chan School of Public Health researchers found that higher levels of optimism are associated with a 15% reduction in dementia risk over 14 years, independent of other known risk factors.

Apr 17, 2026·2 sources
00
Apr 16, 2026

Anti-Amyloid Alzheimer's Drugs Show No Clinically Meaningful Benefit in Cochrane Review

A new Cochrane review found that drugs targeting amyloid beta proteins in the brain likely have no clinically meaningful positive effects while increasing the risk of brain bleeding and swelling.

Apr 16, 2026·1 source
00

Top claims

  • ▪London-based Oyster Therapeutics raised $60 million in Series A-2 funding to advance its preclinical brain-penetrating small molecule degrader research in Alzheimer's disease
  • ▪Biogen reported preliminary Phase 2 data in May 2026 showing tau reduction and cognitive benefit for its antisense oligonucleotide diranersen, though the trial missed its main dose-response goal at week 76
  • ▪Oyster Therapeutics' $60 million Series A-2 round was led by 4BIO Capital, with participation from new investors Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures

Subtopics

Brain health & dementia researchers16Drug Policy, Pricing & Approval16Drug Approval and Clinical Trials15Age related cognitive decline11Alzheimer's disease10Biomarkers & bloodwork testing10Brain longevity8Longevity & biohacking5Neurodegenerative disease5Clinical trials4Drug development4Pharma4Public healthcare4Clinical Trial Design & Evaluation3Longevity & aging3Longevity biotech founders3Neuroplasticity3Preventive longevity physicians3Preventive medicine3Aging biology experts2Biomarkers experts2Cardiovascular aging experts2Clinical evaluation2Cognitive decline2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories